Coronavirus (COVID-19) Update — click here

Press Room

April 2, 2014

bioTheranostics Announces Contract with Three Rivers Provider Network

Company’s Innovative Genomic-Based Tests for Cancer Now Available to 15 Million Members in the United States

FOR IMMEDIATE RELEASE…April 2, 2014…SAN DIEGO…bioTheranostics, Inc., the leading genomic solutions provider for cancer diagnosis, today announced a contract with Three Rivers Provider Network for coverage of the company’s testing services, including CancerTYPE ID® for accurate diagnosis of metastatic cancer, and Breast Cancer IndexSM, which predicts risk of recurrence of early stage, estrogen receptor-positive breast cancer.

Three Rivers Provider Network is one of the country's largest and fastest-growing proprietary PPO networks. As part of the agreement, the genomic tests, which provide valuable information used by healthcare providers in the management of patients diagnosed with breast cancer, as well as patients with metastatic disease, will be available to approximately 15 million covered lives in the United States.

Richard Ding, CEO of bioTheranostics, said, “We are pleased that Three Rivers Provider Network is enhancing its coverage of genomic tests for cancer diagnosis and treatment, and will be offering CancerTYPE ID and Breast Cancer Index to oncologists and patients as important tools in personalized cancer management. We look forward to working with this well-respected organization.”

Ding added that this agreement is a key milestone for bioTheranostics. “bioTheranostics continues to work to gain coverage of our tests with payors who want innovative, high-value molecular testing solutions for cancer,” he said. “The addition of Three Rivers Provider Network brings the total number of lives in the United States under contract for the CancerTYPE ID test to 91 million, further validating its role as the industry-leading molecular cancer classifier.”

CancerTYPE ID predicts tumor type in patients with metastatic cancers, which affect hundreds of thousands of patients in the United States each year and are among the most difficult to diagnose and treat. The CancerTYPE ID test is supported by clinical evidence confirming its diagnostic accuracy, clinical utility in tumor classification, and impact on patient outcomes.

Breast Cancer Index is a second-generation biomarker that addresses unmet clinical needs by accurately predicting both early (0-5 years) and late (5-10 years) distant recurrence, as well as benefit from extended endocrine therapy. Statistics show that about two-thirds of breast cancer patients are estrogen receptor positive, and the risk of late distant recurrence remains a substantial concern, with about 50 percent of recurrences occurring after five years.

About Three Rivers Provider Network

Three Rivers Provider Network (TRPN) has evolved into the largest and fastest-growing proprietary preferred provider organization network in the United States. The TRPN network is comprised of more than 600,000 total providers, including more than 5,000 hospitals and 70,000 ancillary facilities. Through its clients, more than 15 million people have access to the TRPN PPO network. When combined with its global arm, World PPO, the network provides access to healthcare providers representing more than 1.5 million healthcare locations worldwide, with membership exceeding 100 million. For more information, visit

About Biotheranostics

bioTheranostics, Inc., is the leading solution provider for metastatic cancer management, leveraging its unique expertise in gene expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAPaccredited diagnostic laboratory to perform its proprietary tests under the bioT3 Metastatic Cancer Solution brand: CancerTYPE ID®, CancerTARGET ID, and CancerTREATMENT ID. It also offers the Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptorpositive, lymph node-negative breast cancer. bioTheranostics, a bioMérieux company, is based in San Diego. For more information, visit